FR2750866B1 - Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire - Google Patents

Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Info

Publication number
FR2750866B1
FR2750866B1 FR9608243A FR9608243A FR2750866B1 FR 2750866 B1 FR2750866 B1 FR 2750866B1 FR 9608243 A FR9608243 A FR 9608243A FR 9608243 A FR9608243 A FR 9608243A FR 2750866 B1 FR2750866 B1 FR 2750866B1
Authority
FR
France
Prior art keywords
avian
infectious laryngotracheitis
laryngotracheitis virus
living vaccine
recombinant living
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9608243A
Other languages
English (en)
French (fr)
Other versions
FR2750866A1 (fr
Inventor
Jean Christophe Franc Audonnet
Michel Joseph Marie Bublot
Michel Emile Albert Riviere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Rhone Merieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Merieux SA filed Critical Rhone Merieux SA
Priority to FR9608243A priority Critical patent/FR2750866B1/fr
Priority to MA24675A priority patent/MA24222A1/fr
Priority to TNTNSN97109A priority patent/TNSN97109A1/fr
Priority to PCT/FR1997/001138 priority patent/WO1997049826A1/fr
Priority to JP10502456A priority patent/JP2000512844A/ja
Priority to ARP970102799A priority patent/AR008620A1/es
Priority to EP97930591A priority patent/EP0914458A1/fr
Priority to ZA975618A priority patent/ZA975618B/xx
Priority to AU34487/97A priority patent/AU739374B2/en
Priority to IDP972222A priority patent/ID18351A/id
Priority to PE1997000548A priority patent/PE52599A1/es
Priority to CO97036155A priority patent/CO4700303A1/es
Publication of FR2750866A1 publication Critical patent/FR2750866A1/fr
Application granted granted Critical
Publication of FR2750866B1 publication Critical patent/FR2750866B1/fr
Priority to US09/219,932 priority patent/US6153199A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9608243A 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire Expired - Lifetime FR2750866B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9608243A FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
MA24675A MA24222A1 (fr) 1996-06-27 1997-06-23 Vaccin vivant recombinant aviaire utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire.
ZA975618A ZA975618B (en) 1996-06-27 1997-06-25 Avian recombinant live vaccine using as vector the avian infectious laryngotrachetis virus
JP10502456A JP2000512844A (ja) 1996-06-27 1997-06-25 ベクターとして鳥類の感染性喉頭気管炎ウイルスを用いた鳥類用組換え生ワクチン
ARP970102799A AR008620A1 (es) 1996-06-27 1997-06-25 Vacuna viva recombinante, fragmento de adn y virus iltv que la componen
EP97930591A EP0914458A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
TNTNSN97109A TNSN97109A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
AU34487/97A AU739374B2 (en) 1996-06-27 1997-06-25 Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
PCT/FR1997/001138 WO1997049826A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
IDP972222A ID18351A (id) 1996-06-27 1997-06-26 Vaksin hidup rekombinan avian, yang sebagai vektor menggunakan virus laringotracheitis menular avian
PE1997000548A PE52599A1 (es) 1996-06-27 1997-06-27 Vacuna viva recombinante aviaria, que comprende como vector el virus de la laringotraqueitis infecciosa
CO97036155A CO4700303A1 (es) 1996-06-27 1997-06-27 Vacuna viva recombinante aviaria que utiliza como vector el virus de la laringotraqueitis infecciosa aviaria
US09/219,932 US6153199A (en) 1996-06-27 1998-12-23 Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9608243A FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Publications (2)

Publication Number Publication Date
FR2750866A1 FR2750866A1 (fr) 1998-01-16
FR2750866B1 true FR2750866B1 (fr) 1998-11-27

Family

ID=9493649

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9608243A Expired - Lifetime FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Country Status (13)

Country Link
US (1) US6153199A (enExample)
EP (1) EP0914458A1 (enExample)
JP (1) JP2000512844A (enExample)
AR (1) AR008620A1 (enExample)
AU (1) AU739374B2 (enExample)
CO (1) CO4700303A1 (enExample)
FR (1) FR2750866B1 (enExample)
ID (1) ID18351A (enExample)
MA (1) MA24222A1 (enExample)
PE (1) PE52599A1 (enExample)
TN (1) TNSN97109A1 (enExample)
WO (1) WO1997049826A1 (enExample)
ZA (1) ZA975618B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913751B2 (en) 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
WO1999018215A1 (en) 1997-10-03 1999-04-15 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
AR031405A1 (es) * 2000-11-21 2003-09-24 Wyeth Corp Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo
JP2002356441A (ja) * 2001-03-15 2002-12-13 Akzo Nobel Nv 組換え伝染性喉頭気管炎ウイルスワクチン
US7314715B2 (en) * 2001-06-14 2008-01-01 Schering-Plough Animal Health Corporation Recombinant avian herpesvirus useful in vaccine production
HUP0402164A3 (en) 2001-11-16 2010-01-28 Biogen Idec Inc Polycistronic expression of antibodies
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
CA2545886A1 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
JP2007525217A (ja) 2004-02-19 2007-09-06 ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ レプチンプロモーター多型及びその使用
CA2605629C (en) 2005-04-25 2012-06-26 Merial Limited Nipah virus vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
CA2629522A1 (en) 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
KR101715418B1 (ko) 2009-04-03 2017-03-10 메리얼 인코포레이티드 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신
ATE539148T1 (de) 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs
US10633667B2 (en) 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
MX2013001349A (es) * 2010-08-02 2013-06-28 Univ Georgia Virus de laringotraqueitis infecciosa (iltv) modificado y sus usos.
PL2611460T3 (pl) 2010-08-31 2017-02-28 Merial, Inc. Szczepionki przeciw herpeswirusom przenoszone z pomocą wirusa choroby newcastle
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
AP2013007180A0 (en) 2011-04-25 2013-10-31 Advanced Bioscience Lab Inc Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
EA031229B1 (ru) 2011-08-12 2018-12-28 Мериал, Инк. Способ витрификации биологического материала
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US10709341B2 (en) 2012-11-21 2020-07-14 St. Jude Medical Luxembourg Holdings II S.a.r.l. Devices, systems, and methods for pulmonary arterial hypertension (PAH) assessment and treatment
EP2968514A1 (en) 2013-03-12 2016-01-20 Merial, Inc. Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
US9198908B2 (en) 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
EP2845904A1 (en) * 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
WO2016073410A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
NZ738957A (en) 2015-06-23 2019-09-27 Boehringer Ingelheim Animal Health Usa Inc Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748631B1 (en) * 1988-09-13 2006-02-08 Mérial Viral vaccines
WO1992003554A1 (en) * 1990-08-24 1992-03-05 Arthur Webster Pty. Ltd. Infectious laryngotracheitis virus vaccine
WO1993025655A1 (en) * 1992-06-12 1993-12-23 Genencor International, Inc. Enzymatic compositions and methods for producing stonewashed look on indigo-dyed denim fabric
WO1996000791A1 (en) * 1994-06-30 1996-01-11 The Board Of Trustees Of The University Of Illinois Recombinant infectious laryngotracheitis virus and vaccine
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
JP3964458B2 (ja) * 1995-03-23 2007-08-22 シェリング−プロウ・リミテッド 組換え型伝染性喉頭気管炎ウイルスおよびその使用

Also Published As

Publication number Publication date
US6153199A (en) 2000-11-28
AU739374B2 (en) 2001-10-11
JP2000512844A (ja) 2000-10-03
ZA975618B (en) 1998-12-28
CO4700303A1 (es) 1998-12-29
EP0914458A1 (fr) 1999-05-12
AR008620A1 (es) 2000-02-09
WO1997049826A1 (fr) 1997-12-31
AU3448797A (en) 1998-01-14
FR2750866A1 (fr) 1998-01-16
ID18351A (id) 1998-04-02
MA24222A1 (fr) 1997-12-31
TNSN97109A1 (fr) 2005-03-15
PE52599A1 (es) 1999-07-16

Similar Documents

Publication Publication Date Title
FR2750866B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2757061B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2758986B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2728795B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
ATE287728T1 (de) Adjuvierte rekombinante lebendimpfstoffe gegen influenza- oder herpesviren
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
FR2750865B1 (fr) Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
ATE367442T1 (de) Newcastle-krankheitsvirus infektiöser klone, impfstoffe und diagnosetest
DE69730839D1 (de) Hühner polynukleotide impfstoff-formulierung
DK0870508T3 (da) Influenzavaccine
GB9811433D0 (en) Virus vaccine
EP1267626A4 (en) EXPRESSION SYSTEMS FOR RECOMBINANT PARA INFLUENZA VIRUSES AND VACCINE
DE60009609D1 (de) Abgasemissionsregeleinrichtung
DE69533305D1 (de) Lebende rekombinante Vogelvakzine auf eines Vogelherpesvirus gegründet, gegen Gumborokrankheit
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
MX9202781A (es) Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana.
EP0597016A4 (en) Infectious bursal disease virus recombinant poxvirus vaccine.
FR2669346B1 (fr) Vaccin a poxvirus recombinant contre le virus de la rougeole.
BR9712067A (pt) Pept¡dios imunog-nicos de v¡rus da doen-a de febre aftosa
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
GB0100067D0 (en) Diesel exhaust system including NOx trap
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
DE60042130D1 (de) Neue antigene hev-peptide und methoden
BR9915703B1 (pt) mutante do vìrus da raiva recombinante, e, vacina anti-rábica atenuada viva.
AU2002242014A1 (en) Avian vaccine effective against infectious bursal disease virus

Legal Events

Date Code Title Description
CD Change of name or company name
CJ Change in legal form
PLFP Fee payment

Year of fee payment: 20